« Flash, Bang! | Main | Reading List: Making Contact »

Thursday, August 31, 2017

Reading List: Drug Lord

Casey, Doug and John Hunt. Drug Lord. Charlottesville, VA: HighGround Books, 2017. ISBN 978-1-947449-07-7.
This is the second novel in the authors' “High Ground” series, chronicling the exploits of Charles Knight, an entrepreneur and adventurer determined to live his life according to his own moral code, constrained as little as possible by the rules and regulations of coercive and corrupt governments. The first novel, Speculator (October 2016), follows Charles's adventures in Africa as an investor in a junior gold exploration company which just might have made the discovery of the century, and in the financial markets as he seeks to profit from what he's learned digging into the details. Charles comes onto the radar of ambitious government agents seeking to advance their careers by collecting his scalp.

Charles ends up escaping with his freedom and ethics intact, but with much of his fortune forfeit. He decides he's had enough of “the land of the free” and sets out on his sailboat to explore the world and sample the pleasures and opportunities it holds for one who thinks for himself. Having survived several attempts on his life and prevented a war in Africa in the previous novel, seven years later he returns to a really dangerous place, Washington DC, populated by the Morlocks of Mordor.

Charles has an idea for a new business. The crony capitalism of the U.S. pharmaceutical-regulatory complex has inflated the price of widely-used prescription drugs to many times that paid outside the U.S., where these drugs, whose patents have expired under legal regimes less easily manipulated than that of the U.S., are manufactured in a chemically-identical form by thoroughly professional generic drug producers. Charles understands, as fully as any engineer, that wherever there is nonlinearity the possibility for gain exists, and when that nonlinearity is the result of the action of coercive government, the potential profits from circumventing its grasp on the throat of the free market can be very large, indeed.

When Charles's boat docked in the U.S., he had an undeclared cargo: a large number of those little blue pills much in demand by men of a certain age, purchased for pennies from a factory in India through a cut-out in Africa he met on his previous adventure. He has the product, and a supplier able to obtain much more. Now, all he needs is distribution. He must venture into the dark underside of DC to make the connections that can get the product to the customers, and persuade potential partners that they can make much more and far more safely by distributing his products (which don't fall under the purview of the Drug Enforcement Agency, and to which local cops not only don't pay much attention, but may be potential customers).

Meanwhile, Charles's uncle Maurice, who has been managing what was left of his fortune during his absence, has made an investment in a start-up pharmaceutical company, Visioryme, whose first product, VR-210, or Sybillene, is threading its way through the FDA regulatory gauntlet toward approval for use as an antidepressant. Sybillene works through a novel neurochemical pathway, and promises to be an effective treatment for clinical depression while avoiding the many deleterious side effects of other drugs. In fact, Sybillene doesn't appear to have any side effects at all—or hardly any—there's that one curious thing that happened in animal testing, but not wishing to commit corporate seppuku, Visioryme hasn't mentioned it to the regulators or even their major investor, Charles.

Charles pursues his two pharmaceutical ventures in parallel: one in the DC ghetto and Africa; the other in the tidy suburban office park where Visioryme is headquartered. The first business begins to prosper, and Charles must turn his ingenuity to solving the problems attendant to any burgeoning enterprise: supply, transportation, relations with competitors (who, in this sector of the economy, not only are often armed but inclined to shoot first), expanding the product offerings, growing the distribution channels, and dealing with all of the money that's coming in, entirely in cash, without coming onto the radar of any of the organs of the slavers and their pervasive snooper-state.

Meanwhile, Sybillene finally obtains FDA approval, and Visioryme begins to take off and ramp up production. Charles's connections in Africa help the company obtain the supplies of bamboo required in production of the drug. It seems like he now has two successful ventures, on the dark and light sides, respectively, of the pharmaceutical business (which is dark and which is light depending on your view of the FDA).

Then, curious reports start to come in about doctors prescribing Sybillene off-label in large doses to their well-heeled patients. Off-label prescription is completely legal and not uncommon, but one wonders what's going on. Then there's the talk Charles is picking up from his other venture of demand for a new drug on the street: Sybillene, which goes under names such as Fey, Vatic, Augur, Covfefe, and most commonly, Naked Emperor. Charles's lead distributor reports, “It helps people see lies for what they are, and liars too. I dunno. I never tried it. Lots of people are asking though. Society types. Lawyers, businessmen, doctors, even cops.” It appears that Sybillene, or Naked Emperor, taken in a high dose, is a powerful nootropic which doesn't so much increase intelligence as, the opposite of most psychoactive drugs, allows the user to think more clearly, and see through the deception that pollutes the intellectual landscape of a modern, “developed”, society.

In that fœtid city by the Potomac, the threat posed by such clear thinking dwarfs that of other “controlled substances” which merely turn their users into zombies. Those atop an empire built on deceit, deficits, and debt cannot run the risk of a growing fraction of the population beginning to see through the funny money, Ponzi financing, Potemkin military, manipulation of public opinion, erosion of the natural rights of citizens, and the sham which is replacing the last vestiges of consensual government. Perforce, Sybillene must become Public Enemy Number One, and if a bit of lying and even murder is required, well, that's the price of preserving the government's ability to lie and murder.

Suddenly, Charles is involved in two illegal pharmaceutical ventures. As any wise entrepreneur would immediately ask himself, “might there be synergies?”

Thus begins a compelling, instructive, and inspiring tale of entrepreneurship and morality confronted with dark forces constrained by no limits whatsoever. We encounter friends and foes from the first novel, as once again Charles finds himself on point position defending those in the enterprises he has created. As I said in my review of Speculator, this book reminds me of Ayn Rand's The Fountainhead, but it is even more effective because Charles Knight is not a super-hero but rather a person with a strong sense of right and wrong who is making up his life as he goes along and learning from the experiences he has: good and bad, success and failure. Charles Knight, even without Naked Emperor, has that gift of seeing things precisely as they are, unobscured by the fog, cant, spin, and lies which are the principal products of the city in which it is set.

These novels are not just page-turning thrillers, they're simultaneously an introductory course in becoming an international man (or woman), transcending the lies of the increasingly obsolescent nation-state, and finding the liberty that comes from seizing control of one's own destiny. They may be the most powerful fictional recruiting tool for the libertarian and anarcho-capitalist world view since the works of Ayn Rand and L. Neil Smith. Speculator was my fiction book of the year for 2016, and this sequel is in the running for 2017.

Posted at August 31, 2017 22:20